Compare Eos Energy Enterprises Inc (EOSE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Sana Biotechnology Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.24 (market cap $1.54B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Eos Energy Enterprises Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | SANA | |
|---|---|---|
Market Cap | $1.54B | $1.13B |
Sector | Energy | Health |
52-Week High | $19.19 | $5.92 |
52-Week Low | $3.14 | $2.68 |
Enterprise Value | $1.88B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.24, up 4.69% today, with a bullish technical signal but mixed fundamentals. Revenue grew to $214 million in 2026 from $114 million in 2025, yet net losses remain deep at -$529 million. Analyst consensus is a $7.75 price target with 30% buy ratings, though recent news highlights shareholder litigation and concerns over dilution and revenue quality.
The outlook hinges on Eos scaling its energy storage business profitably. Opportunities exist if manufacturing consolidation and project execution improve margins, but high cash burn, intense competition, and reliance on financing pose significant risks to shareholder value.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
